JP2023546452A - 眼障害を処置するための化合物および方法 - Google Patents

眼障害を処置するための化合物および方法 Download PDF

Info

Publication number
JP2023546452A
JP2023546452A JP2023524274A JP2023524274A JP2023546452A JP 2023546452 A JP2023546452 A JP 2023546452A JP 2023524274 A JP2023524274 A JP 2023524274A JP 2023524274 A JP2023524274 A JP 2023524274A JP 2023546452 A JP2023546452 A JP 2023546452A
Authority
JP
Japan
Prior art keywords
substituted
radical
alkyl
pharmaceutically acceptable
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546452A5 (cg-RX-API-DMAC10.html
Inventor
ボスワース,チャールズ
スチュワート,マーク,リチャード
バラッシュ,ヒラ
チャップマン,ニコラス,アンドリュー
ブルク,ロバート,エム.
ホームズ,イアン
グリーソン,マルク
アルスター,ヤイル
ラファエリ,オマー
ダン,ジョナサン
Original Assignee
アズーラ オフサルミックス エルティーディー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アズーラ オフサルミックス エルティーディー. filed Critical アズーラ オフサルミックス エルティーディー.
Publication of JP2023546452A publication Critical patent/JP2023546452A/ja
Publication of JP2023546452A5 publication Critical patent/JP2023546452A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023524274A 2020-10-21 2021-10-20 眼障害を処置するための化合物および方法 Pending JP2023546452A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094808P 2020-10-21 2020-10-21
US63/094,808 2020-10-21
PCT/IB2021/000708 WO2022084739A1 (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders

Publications (2)

Publication Number Publication Date
JP2023546452A true JP2023546452A (ja) 2023-11-02
JP2023546452A5 JP2023546452A5 (cg-RX-API-DMAC10.html) 2024-10-29

Family

ID=81290138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524274A Pending JP2023546452A (ja) 2020-10-21 2021-10-20 眼障害を処置するための化合物および方法

Country Status (10)

Country Link
US (1) US20230399317A1 (cg-RX-API-DMAC10.html)
EP (1) EP4232034A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023546452A (cg-RX-API-DMAC10.html)
KR (1) KR20230110516A (cg-RX-API-DMAC10.html)
CN (1) CN116635032A (cg-RX-API-DMAC10.html)
AU (1) AU2021365530A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196146A1 (cg-RX-API-DMAC10.html)
IL (1) IL302174A (cg-RX-API-DMAC10.html)
MX (1) MX2023004538A (cg-RX-API-DMAC10.html)
WO (1) WO2022084739A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
WO2024100454A2 (en) * 2022-11-11 2024-05-16 Azura Ophthalmics Ltd. Composition and methods for improving signs and symptoms of ocular disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500683A (ja) * 2007-10-19 2011-01-06 サーコード コーポレーション 糖尿病性網膜症の治療のための組成物及び方法
JP2018533622A (ja) * 2015-09-28 2018-11-15 アズーラ オフサルミックス エルティーディー. マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
WO2019053607A1 (en) * 2017-09-18 2019-03-21 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING LIFITEGRAST
WO2019096996A1 (en) * 2017-11-17 2019-05-23 Medichem, S.A. A process to obtain a tetrahydroisoquinoline derivative
JP2020515533A (ja) * 2017-03-29 2020-05-28 アズーラ オフサルミックス エルティーディー. マイボーム腺脂質分泌を増加させるための薬剤
JP2020523406A (ja) * 2017-05-19 2020-08-06 オクジェン アイエヌシー. 眼科用組成物および使用方法
JP7700045B2 (ja) * 2019-04-18 2025-06-30 アズーラ オフサルミックス エルティーディー. 眼障害を処置するための化合物および方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
EP3827823A1 (en) * 2012-12-19 2021-06-02 Novartis AG Lfa-1 inhibitor formulations
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CA3020713A1 (en) * 2016-04-19 2017-10-26 Azura Ophthalmics Ltd. Compositions for the treatment of hyperkeratosis disorders
US20180333357A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Nanoemulsions with anti-inflammatory activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500683A (ja) * 2007-10-19 2011-01-06 サーコード コーポレーション 糖尿病性網膜症の治療のための組成物及び方法
JP2018533622A (ja) * 2015-09-28 2018-11-15 アズーラ オフサルミックス エルティーディー. マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
JP2020515533A (ja) * 2017-03-29 2020-05-28 アズーラ オフサルミックス エルティーディー. マイボーム腺脂質分泌を増加させるための薬剤
JP2020523406A (ja) * 2017-05-19 2020-08-06 オクジェン アイエヌシー. 眼科用組成物および使用方法
WO2019053607A1 (en) * 2017-09-18 2019-03-21 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING LIFITEGRAST
WO2019096996A1 (en) * 2017-11-17 2019-05-23 Medichem, S.A. A process to obtain a tetrahydroisoquinoline derivative
JP7700045B2 (ja) * 2019-04-18 2025-06-30 アズーラ オフサルミックス エルティーディー. 眼障害を処置するための化合物および方法

Also Published As

Publication number Publication date
EP4232034A1 (en) 2023-08-30
CN116635032A (zh) 2023-08-22
US20230399317A1 (en) 2023-12-14
CA3196146A1 (en) 2022-04-28
KR20230110516A (ko) 2023-07-24
IL302174A (en) 2023-06-01
AU2021365530A1 (en) 2023-06-15
AU2021365530A9 (en) 2024-02-08
EP4232034A4 (en) 2024-12-04
MX2023004538A (es) 2023-06-19
WO2022084739A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
US11643429B2 (en) Compounds and methods for the treatment of ocular disorders
JP7700045B2 (ja) 眼障害を処置するための化合物および方法
JP2023546453A (ja) 眼障害を処置するための化合物および方法
JP2023546915A (ja) 眼障害を処置するための化合物および方法
KR20230110516A (ko) 눈 장애의 치료를 위한 화합물 및 방법
US20250042931A1 (en) Compounds and methods for the treatment of ocular disorders
CN116940570A (zh) 用于治疗眼部病症的化合物和方法
HK40100091A (en) Compounds and methods for the treatment of ocular disorders
HK40100700A (en) Compounds and methods for the treatment of ocular disorders
HK40068671A (en) Compounds and methods for the treatment of ocular disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260805